Pappone 2006.

Methods	Randomised controlled trial.
Participants	Included patients with: Age >18 or<70 years; Creatinine concentration <1.5 mg/dl; AF history > 6 months; AF burden > 2 episodes/month in the last 6 months. 198 patients were included. 99 were arranged to CPVA group, and 99 to ADT group. Age: 55+/‐10 years in CPVA group, and 57+/‐10 years in ADT group. % of male: 69/99 (70%) in CPVA group, and 64/99 (65%) in ADT group. Follow‐up: 12 months. Location: Milan, Italy.
Interventions	Ablation group: Circumferential pulmonary vein ablation. ADT group: amiodarone, flecainide, or sotalol, either as single drugs or in combination, at the maximum tolerable doses.
Outcomes	Freedom from documented recurrent atrial tachycardia.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient detail was provided.
Allocation concealment (selection bias)	Unclear risk	B‐Unclear. The authors did not depict allocation concealment method.
Blinding	High risk	Blinding was not reported.
Incomplete outcome data addressed	High risk	There were no patients withdrawn or lost to follow up.
Adequate sequence generation	Unclear risk	It was not addressed.